First-line Chemotherapy for Recurrent Cervical Cancer

Status Completed

Clinical Trial Summary

The response rate of traditional first-line chemotherapy for recurrent or persistent advanced cervical cancer was low. This single arm, open, phase II trial would recruit 37 eligible patients. A combination of cisplatin, paclitaxel and apatinib would be given for first 23 patients. If at least 13 patients achieved complete or partial remission, the same regimen would be given for rest patients. The primary end is overall response rate (ORR). The second ends include progression-free survival, overall survival, disease control rate, remission duration, and adverse events. A molecular testing, mainly consisting of genomic analysis, will be carried in the oncologic tissues.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Apatinib
Carcinoma
Chemotherapy
Persistent Advanced Cervical Carcinoma
Recurrent Cervical Carcinoma
Targeted Therapy
Uterine Cervical Neoplasms
Vascular Endothelial Growth Factor 2 Inhibitor

Clinical Trial Details

NCT number	NCT04188847
Study type	Interventional
Source	Peking Union Medical College Hospital
Contact
Status	Completed
Phase	Phase 2
Start date	December 6, 2019
Completion date	March 13, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03652727` - FX vs. ECG Guidance for PICC Insertion	N/A
Not yet recruiting	`NCT05856656` - Music Therapy as a Tool for Anxiety Reduction in Localized Breast Cancer	N/A
Active, not recruiting	`NCT02959541` - PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer	N/A
Completed	`NCT00757094` - Safety and Feasibility of Fasting While Receiving Chemotherapy	N/A
Recruiting	`NCT00797238` - DNA Repair Genes and Outcomes in Patients With Stage III NSCLC	N/A
Not yet recruiting	`NCT05927857` - Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .	Phase 1/Phase 2
Recruiting	`NCT04453826` - Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma	Phase 3
Completed	`NCT04466332` - Comparison of Two ECG Guided PICC Insertion Techniques	N/A
Not yet recruiting	`NCT04055038` - Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)	Phase 2/Phase 3
Recruiting	`NCT03701607` - Effect of Chemotherapy on PD-L1 in NSCLC
Recruiting	`NCT04024241` - Medium Dose of Cytarabine and Mitoxantrone
Recruiting	`NCT06208436` - The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer
Recruiting	`NCT05306301` - Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients	Phase 2
Active, not recruiting	`NCT02304640` - Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients
Completed	`NCT02298972` - Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer	N/A
Terminated	`NCT01249001` - Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents	Phase 2
Recruiting	`NCT03089892` - A Perspective Study of Cancer-related Fatigue in Gynecologic Cancer Patients Under Chemotherapy	N/A
Recruiting	`NCT05125055` - Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC	Phase 2/Phase 3
Recruiting	`NCT04472403` - Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
Terminated	`NCT02982694` - Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer	Phase 2